Table 3.
Overview of principal BLVR-Valve Studies
| Study/Author | Year | n | Follow-up time, M | Δ FEV1 | Δ RV L | Δ 6MWT m | Δ SGRQ point | TLVR mL |
|---|---|---|---|---|---|---|---|---|
| Sciurba et al. [14] | 2010 | 220 | 6 | +34.5 mL, +4.3% | * | +9.3 | −2.8 | * |
| Herth et al. [15] | 2012 | 111 | 12 | +15.0% | * | +22% | −5.0 | * |
| Davey et al. [16] | 2015 | 25 | 6 | +60 mL, +8.7% | −0.26 | +25.0 | −4.4 | * |
| Valipour et al. [17] | 2016 | 43 | 3 | +100 mL | −0.42 | +22.6 | −8.6 | −1195 |
| Klooster et al. [18] | 2017 | 64 | 12 | +17.0% | −0.68 | +61.0 | −11.0 | * |
| Fiorelli et al. [19] | 2017 | 33 | 60 | +17.0% | −39% | +91.0 | −17.0 | * |
| Kemp et al. [20] | 2017 | 65 | 6 | +140 mL, +20.7% | −0.66 | +36.2 | −7.2 | * |
| Welling et al. [13] | 2018 | 318 | 6 | +53.4 mL | −0.20 | * | −4.3 | −463 |
|
| ||||||||
| Overview of Complications | ||||||||
| Study/Author | Year | n | Follow-up, M | Pneumonia | COPD Exc. | PNX | Valve EMR | Death |
|
| ||||||||
| Sciurba et al. [14] | 2010 | 220 | 6 | 3.2% | 9.3% | 4.2% | * | 0.9% |
| Herth et al. [15] | 2012 | 111 | 12 | 11.7% | 42.3% | 8.0% | * | 5.4% |
| Davey et al. [16] | 2015 | 25 | 6 | 8.0% | 64.0% | 8.0% | 20.0% | 8.0% |
| Valipour et al. [17] | 2016 | 43 | 3 | 0 | 16.3% | 25.6% | 7.0% | 0 |
| Klooster et al. [18] | 2017 | 64 | 12 | 8.0% | 14.0% | 22.0% | 17.0% | 3.0% |
| Fiorelli et al. [19] | 2017 | 33 | 60 | 3.0% | * | 6.0% | 5.0% | 0 |
| Kemp et al. [20] | 2017 | 65 | 6 | 4.6% | 4.6% | 29.2% | 1.5% | 1.5% |
n: patient population; M: month; TLVR: target lobar volume reduction; SGRQ: St George’s Respiratory Questionnaire total score; COPD: chronic obstructive pulmonary disease; Exc: Exacerbation; PNX: pneumothorax; EMR: Expectoration, migration, and replacement; FEV1: forced expiration volume in the 1 s; Δ: change;
*
no data